These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

899 related articles for article (PubMed ID: 17414590)

  • 21. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
    Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.
    Bermúdez V; Cano R; Cano C; Bermúdez F; Leal E; Acosta K; Mengual E; Arraiz N; Briceño C; Gómez J; Bustamante M; Aparicio D; Cabrera M; Valdelamar L; Rodriguez M; Manuel V; Hernández R
    Am J Ther; 2008; 15(4):409-16. PubMed ID: 18645347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study.
    Pfützner A; Derwahl M; Jacob S; Hohberg C; Blümner E; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2010 Aug; 12(8):599-604. PubMed ID: 20615100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
    Derosa G; Gaddi AV; Piccinni MN; Salvadeo S; Ciccarelli L; Fogari E; Ghelfi M; Ferrari I; Cicero AF
    Diabetes Obes Metab; 2006 Mar; 8(2):197-205. PubMed ID: 16448524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.
    Ramachandran A; Snehalatha C; Salini J; Vijay V
    J Assoc Physicians India; 2004 Jun; 52():459-63. PubMed ID: 15645955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes.
    Beljić-Živković T; Marjanović-Petković M; Vuksanović M; Soldatović I; Kanlić D; Topalov D
    Srp Arh Celok Lek; 2016; 144(9-10):497-502. PubMed ID: 29652465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.
    Henry RR; Buse JB; Wu H; Durrwell L; Mingrino R; Jaekel K; El Azzouzi B; Andjelkovic M; Herz M
    Diabetes Obes Metab; 2015 Jun; 17(6):560-565. PubMed ID: 25728612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
    Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
    Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations.
    Gadgade A; Kudgi AS; Kamath A; Kamath P; Adhikari P; Revappala NS; Hadigal S; Natarajan S; Shenoy N; Chowta MN
    Curr Diabetes Rev; 2020; 16(5):503-508. PubMed ID: 31250763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
    Perl S; Cook W; Wei C; Ohman P; Hirshberg B
    Clin Ther; 2016 Dec; 38(12):2578-2588. PubMed ID: 27823868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin.
    Pareek A; Chandurkar NB; Salkar HR; Borkar MS; Tiwari D
    Am J Ther; 2013 Jan; 20(1):41-7. PubMed ID: 21326082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thiazolidinedione addition reduces the serum retinol-binding protein 4 in type 2 diabetic patients treated with metformin and sulfonylurea.
    Lin KD; Chang YH; Wang CL; Yang YH; Hsiao PJ; Li TH; Shin SJ
    Transl Res; 2008 Jun; 151(6):309-14. PubMed ID: 18514142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes.
    Tan MH; Glazer NB; Johns D; Widel M; Gilmore KJ
    Curr Med Res Opin; 2004 May; 20(5):723-8. PubMed ID: 15140339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.
    Lim S; An JH; Shin H; Khang AR; Lee Y; Ahn HY; Yoon JW; Kang SM; Choi SH; Cho YM; Park KS; Jang HC
    Clin Endocrinol (Oxf); 2012 Aug; 77(2):215-23. PubMed ID: 21955147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas.
    Emoto M; Nishizawa Y; Maekawa K; Hiura Y; Kanda H; Kawagishi T; Shoji T; Okuno Y; Morii H
    Diabetes Care; 1999 May; 22(5):818-22. PubMed ID: 10332688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.
    Gupta AK; Smith SR; Greenway FL; Bray GA
    Diabetes Obes Metab; 2009 Apr; 11(4):330-7. PubMed ID: 19267711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.